- Home
- AFRI vs DERM Comparison
AFRI vs DERM Comparison
Compare AFRI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- DERM
- Stock Information
- Founded
- AFRI 1943
- DERM 2014
- Country
- AFRI Gibraltar
- DERM United States
- Employees
- AFRI N/A
- DERM N/A
- Industry
- AFRI Packaged Foods
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- AFRI Consumer Staples
- DERM Health Care
- Exchange
- AFRI Nasdaq
- DERM Nasdaq
- Market Cap
- AFRI 214.9M
- DERM 181.0M
- IPO Year
- AFRI N/A
- DERM 2021
- Fundamental
- Price
- AFRI $7.78
- DERM $7.81
- Analyst Decision
- AFRI
- DERM Strong Buy
- Analyst Count
- AFRI 0
- DERM 2
- Target Price
- AFRI N/A
- DERM $10.00
- AVG Volume (30 Days)
- AFRI 19.2K
- DERM 104.4K
- Earning Date
- AFRI 06-10-2025
- DERM 05-14-2025
- Dividend Yield
- AFRI N/A
- DERM N/A
- EPS Growth
- AFRI N/A
- DERM N/A
- EPS
- AFRI N/A
- DERM N/A
- Revenue
- AFRI $274,223,000.00
- DERM $56,243,000.00
- Revenue This Year
- AFRI N/A
- DERM $29.83
- Revenue Next Year
- AFRI N/A
- DERM $54.88
- P/E Ratio
- AFRI N/A
- DERM N/A
- Revenue Growth
- AFRI N/A
- DERM N/A
- 52 Week Low
- AFRI $7.54
- DERM $3.54
- 52 Week High
- AFRI $12.00
- DERM $8.25
- Technical
- Relative Strength Index (RSI)
- AFRI 34.98
- DERM 61.06
- Support Level
- AFRI $7.62
- DERM $6.55
- Resistance Level
- AFRI $7.89
- DERM $7.00
- Average True Range (ATR)
- AFRI 0.16
- DERM 0.65
- MACD
- AFRI 0.03
- DERM 0.11
- Stochastic Oscillator
- AFRI 54.69
- DERM 81.56
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.